INT67283

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.47
First Reported 1996
Last Reported 2008
Negated 0
Speculated 0
Reported most in Abstract
Documents 8
Total Number 9
Disease Relevance 5.02
Pain Relevance 1.01

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Serpinc1)
Anatomy Link Frequency
Epithelial cells 1
Serpinc1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Bioavailability 10 100.00 Very High Very High Very High
cva 28 98.40 Very High Very High Very High
tolerance 2 97.96 Very High Very High Very High
abdominal pain 1 93.52 High High
Migraine 1 79.40 Quite High
aspirin 10 62.24 Quite High
headache 2 60.32 Quite High
Angina 4 59.92 Quite High
Inflammatory response 8 33.68 Quite Low
cytokine 12 23.60 Low Low
Disease Link Frequency Relevance Heat
Deep Vein Thrombosis 5 99.78 Very High Very High Very High
Cv General 3 Under Development 25 98.40 Very High Very High Very High
Coagulation Disorder 5 97.92 Very High Very High Very High
Abdominal Pain 1 93.52 High High
Syndrome 9 92.32 High High
Hemorrhage 40 91.72 High High
Pancytopenia 2 91.32 High High
Obesity 1 89.80 High High
Leukemia 2 89.64 High High
Systemic Lupus Erythematosus 1 89.24 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Mesenteric venous thromboses are often associated with antithrombin III deficiency.
antithrombin III Binding (associated) of associated with deep vein thrombosis
1) Confidence 0.47 Published 1997 Journal J Mal Vasc Section Abstract Doc Link 9479609 Disease Relevance 0.68 Pain Relevance 0.13
They should also screen for protein C, protein S, and antithrombin III deficiency and for acquired antiphospholipid antibodies.
antithrombin III Binding (screen) of
2) Confidence 0.05 Published 1996 Journal Practitioner Section Abstract Doc Link 8984464 Disease Relevance 1.27 Pain Relevance 0.17
The favorable pharmacologic properties of LMWHs include a binding affinity for antithrombin III, anti-factor IIa activity, excellent bioavailability, minimal protein binding, predictable anticoagulant response, and clinical tolerance by patients.
antithrombin III Binding (affinity) of associated with tolerance and bioavailability
3) Confidence 0.05 Published 1998 Journal Am. J. Cardiol. Section Abstract Doc Link 9737475 Disease Relevance 0.35 Pain Relevance 0.22
The favorable pharmacologic properties of LMWHs include a binding affinity for antithrombin III, anti-factor IIa activity, excellent bioavailability, minimal protein binding, predictable anticoagulant response, and clinical tolerance by patients.
antithrombin III Binding (binding) of associated with tolerance and bioavailability
4) Confidence 0.05 Published 1998 Journal Am. J. Cardiol. Section Abstract Doc Link 9737475 Disease Relevance 0.42 Pain Relevance 0.24
The heparin-antithrombin-III complex also has inhibitory effects on factor Xa and other clotting factors.
antithrombin-III Binding (complex) of associated with coagulation disorder
5) Confidence 0.02 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2496975 Disease Relevance 0.10 Pain Relevance 0
As well as improving bioavailability, once binding to antithrombin-III occurs, greater relative specificity for factor Xa is provided when compared to UFH, producing enhanced blockade of the coagulation cascade upstream of thrombin generation.
antithrombin-III Binding (binding) of associated with bioavailability
6) Confidence 0.02 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2496975 Disease Relevance 0.37 Pain Relevance 0.13
Epithelial cells express on their cell surface glycoaminoglycans able to bind to plasma Antithrombin (AT) and leading to the generation of TAT complexes in the alveolar fluid [41].
Antithrombin Binding (bind) of in Epithelial cells
7) Confidence 0.02 Published 2006 Journal Respir Res Section Body Doc Link PMC1435891 Disease Relevance 0.15 Pain Relevance 0
Moreover, an excessive elevation of plasmin-antiplasmin complexes (9,200 ng/ml; normal range: 10-150), an elevated D-dimer, and an increase in thrombin-antithrombin III complexes were found.
thrombin-antithrombin III Binding (complexes) of
8) Confidence 0.01 Published 1999 Journal Am. J. Hematol. Section Abstract Doc Link 10331514 Disease Relevance 0.84 Pain Relevance 0.06
Moreover, an excessive elevation of plasmin-antiplasmin complexes (9,200 ng/ml; normal range: 10-150), an elevated D-dimer, and an increase in thrombin-antithrombin III complexes were found.
thrombin-antithrombin III Binding (complexes) of
9) Confidence 0.01 Published 1999 Journal Am. J. Hematol. Section Abstract Doc Link 10331514 Disease Relevance 0.84 Pain Relevance 0.06

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox